Which Type 2 Endoleaks Should We Intervene?

This work emphasizes the need to be conservative with type 2 endoleaks, and the need for long-term prospective information to learn about the advantages of intervention.

¿Qué endoleaks tipo 2 deben ser intervenidos?

The presence of type 2 endoleaks is associated with reintervention, as it was historically assumed that they increase the risk of sac rupture. However, this new research, published in Eur J Vasc Endovasc Surg, suggests that there are no differences in mortality after 10 years of follow-up among those who underwent a reintervention and those treated conservatively.

This retrospective cohort from several centers in the Netherlands included all patients who underwent endovascular repair of an infrarenal abdominal aortic aneurysm between 2007 and 2012.

The primary endpoint was survival of patients with type 2 endoleak vs. patients without endoleak. Secondary endpoints included sac growth, aneurysm rupture, and reintervention.

About 2018 patients were included, with a mean follow-up of >5 years and, in some cases, >10 years.

No differences were observed in terms of mortality between patients with and without endoleaks (n = 388 and n = 1630, respectively; p = 0.54). More importantly, among the 388 patients with endoleak, no differences were observed between patients who underwent reintervention and those treated conservatively


Read also: Un dolor de cabeza para los cardiólogos: Isquemia con enfermedad NO obstructiva.


Sac growth was detected in 89 patients with endoleak, which resulted in treatment for half the group only (n = 44, 49.8%).

In virtually all patients who received type 2 endoleak treatment for sac growth (n = 41, 93.1%), the sac continued to grow and was left without further intervention.

In 4 out of 388 patients with type 2 endoleak, the sac ruptured. According to the multivariate analysis, mortality predictors were age, surgical risk, and maximum iliac diameter. Endoleak presence, sac growth, and endoleak intervention did not predict mortality.

Conclusion

The long-term survival of patients with type 2 endoleak is similar to that of patients without it. Furthermore, no benefit was observed in reintervened patients vs. those treated conservatively. A prospective study is needed to define the prognosis of type 2 endoleaks and their need of intervention.

PIIS1078588421000678

Original Title: Type 2 Endoleak With or Without Intervention and Survival After Endovascular Aneurysm Repair.

Reference: Sana Mulay et al. Eur J Vasc Endovasc Surg. 2021 May;61(5):779-786. doi: 10.1016/j.ejvs.2021.01.017.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE

Pulmonary embolism (PE) continues to be the third cause of cardiovascular mortality. The current clinical guidelines recommend anticoagulation in intermediate risk patients presenting right...

Atherosclerotic Renal Artery Stenosis: To Revascularize or Not

At long term, atherosclerotic renal artery stenosis (RAS) can lead to hypertension, chronic kidney disease, and cardiac failure. Historically, these patients have been referred...

Endovascular Management of Chronic TEPH: Is Coronary Management Extrapolatable in This Scenario?

Chronic thromboembolic pulmonary hypertension (CTEPH) is a condition that causes significant functional limitation. Its surgical treatment, known as pulmonary endarterectomy (PEA), has improved the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...